Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status Prescription
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-701; 64918-1900; 53104-7633; 70515-712; 24002-0016; 70515-711; 70515-737; 64918-1112
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinorrhoea22.02.05.010--
Secondary adrenocortical insufficiency14.11.01.014; 05.01.02.003--Not Available
Sinus headache22.02.05.023; 17.14.01.002--
Sinusitis22.07.03.007; 11.01.13.005--
Somnolence19.02.05.003; 17.02.04.0060.001570%
Sputum discoloured22.02.03.0100.003141%Not Available
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.0180.001570%Not Available
Swollen tongue07.14.02.003; 23.04.01.014; 10.01.05.015--Not Available
Tachycardia02.03.02.0070.001570%Not Available
Throat irritation22.02.05.013; 07.05.03.0040.001570%Not Available
Tonsillitis22.07.03.008; 11.01.13.006--Not Available
Type I hypersensitivity10.01.03.006--Not Available
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Viral upper respiratory tract infection22.07.02.004; 11.05.04.007--Not Available
Vision blurred06.02.06.007; 17.17.01.0100.002356%
Weight increased13.15.01.006--
Wheezing22.03.01.0090.003926%
White blood cell count increased13.01.06.013--Not Available
Osteopenia15.02.03.003; 14.04.04.004--Not Available
Nocturnal dyspnoea22.02.01.019; 02.01.03.0050.002356%Not Available
Muscle strain15.05.07.002; 12.01.07.004--Not Available
Contusion23.03.11.002; 15.03.01.008; 12.01.06.001; 24.07.06.001--
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Respiratory tract congestion22.02.07.0030.001570%Not Available
Nasal discomfort22.02.05.020--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages